Vanguard Group Inc. Increases Stock Holdings in Hinge Health Inc. $HNGE

Vanguard Group Inc. grew its stake in Hinge Health Inc. (NYSE:HNGE) by 110.5% during the 4th quarter, Holdings Channel reports. The firm owned 2,605,532 shares of the company’s stock after purchasing an additional 1,367,693 shares during the quarter. Vanguard Group Inc.’s holdings in Hinge Health were worth $121,027,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Hinge Health during the 3rd quarter worth $37,000. First Horizon Corp boosted its holdings in shares of Hinge Health by 163.9% during the 4th quarter. First Horizon Corp now owns 855 shares of the company’s stock worth $40,000 after purchasing an additional 531 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Hinge Health during the 3rd quarter worth approximately $49,000. Jones Financial Companies Lllp grew its position in shares of Hinge Health by 348.0% in the third quarter. Jones Financial Companies Lllp now owns 1,120 shares of the company’s stock valued at $54,000 after purchasing an additional 870 shares in the last quarter. Finally, Rakuten Investment Management Inc. acquired a new stake in shares of Hinge Health in the third quarter valued at approximately $81,000.

Hinge Health Stock Performance

NYSE HNGE opened at $55.17 on Wednesday. Hinge Health Inc. has a one year low of $30.08 and a one year high of $62.18. The firm has a 50 day simple moving average of $43.58 and a 200-day simple moving average of $44.12. The firm has a market cap of $4.35 billion and a price-to-earnings ratio of -4.47.

Hinge Health (NYSE:HNGE) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.33. The business had revenue of $182.31 million during the quarter. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The business’s quarterly revenue was up 47.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.30 EPS. Equities analysts predict that Hinge Health Inc. will post 0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James Budge sold 11,006 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $42.26, for a total value of $465,113.56. Following the completion of the transaction, the chief financial officer owned 401,427 shares in the company, valued at approximately $16,964,305.02. This represents a 2.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Gabriel M.I. Mecklenburg sold 166,666 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $45.32, for a total transaction of $7,553,303.12. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 648,576 shares of company stock worth $30,122,850. Insiders own 18.92% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Citizens Jmp boosted their price objective on Hinge Health from $65.00 to $80.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Weiss Ratings raised shares of Hinge Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 6th. Freedom Capital raised shares of Hinge Health to a “strong-buy” rating in a report on Thursday, January 22nd. Evercore reaffirmed an “outperform” rating and set a $45.00 target price on shares of Hinge Health in a research note on Wednesday, April 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $95.00 price target on shares of Hinge Health in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $67.40.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.